Compare Inovio Pharmaceuticals Inc (INO) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Valero Energy Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Valero Energy Corporation trades at $312 (market cap $93.03B). The key difference: Valero Energy Corporation is far larger — about 1042.1× Inovio Pharmaceuticals Inc's market cap, and Valero Energy Corporation pays a 1.53% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | VLO | |
|---|---|---|
Market Cap | $89.27M | $93.03B |
Sector | Health | Energy |
52-Week High | $2.87 | $313.31 |
52-Week Low | $1.05 | $131.77 |
Enterprise Value | $60.28M | $98.79B |
Dividend Yield | — | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Valero Energy (VLO) trades at $314.81, up 1.67% on the day, with strong technical momentum and bullish moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.22 surpassing expectations of $3.16. Revenue declined to $122.69 billion in 2025, but net income margin held at 3.37%, supported by robust refining margins. Recent news highlights strong fuel demand and elevated crack spreads benefiting Valero's outlook.
The outlook remains positive given earnings beats, analyst buy ratings (55.55%), and refining margin tailwinds. However, declining revenue trends, high RSI levels suggesting overbought conditions, and exposure to volatile energy markets pose risks. The consensus price target of $276.22 implies potential downside from current levels, requiring careful monitoring of Q2 2026 earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
